Antiviral therapeutics for COVID-19 in nonhospitalized patients prevent progression to
severe illness, hospitalization, and death. Despite their proven benefit, utilization of these …

In a randomized clinical trial of 86 hospitalized COVID-19 patients comparing standard care
to treatment with 300mL convalescent plasma containing high titers of neutralizing SARS …

Importance Patients who are immunocompromised have increased risk for morbidity and
mortality associated with coronavirus disease 2019 (COVID-19) because they less …

The efficacy of convalescent plasma for coronavirus disease 2019 (COVID-19) is unclear.
Although most randomized controlled trials have shown negative results, uncontrolled …

Background Convalescent plasma has been one of the most common treatments for COVID-
19, but most clinical trial data to date have not supported its efficacy. Research Question Is …

Substantial progresshas been made in therapeutics for nonhospitalizedpatientswithCOVID-
19, butsupplyofand access to treatment remain limited. This Viewpoint summarizes currently …

Structured abstract for full paper Background After recovery from COVID-19, most patients
have anti-SARS-CoV-2 neutralizing antibodies. Their convalescent plasma could be an …

Description: Coronavirus disease 2019 convalescent plasma (CCP) has emerged as a
potential treatment of COVID-19. However, meta-analysis data and recommendations are …

Background There is currently no treatment known to alter the course of coronavirus disease
2019 (COVID-19). Convalescent plasma has been used to treat a number of infections …

Abstract Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2), is a new human disease with few effective …